Emerging Growth Company Status. From the time of initial confidential submission of the Registration Statement to the Commission (or, if earlier, the first date on which the Company engaged in any Section 5(d) Written Communication or any Section 5(d) Oral Communication) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).
Appears in 152 contracts
Samples: Underwriting Agreement (Telix Pharmaceuticals LTD), Underwriting Agreement (Adicet Bio, Inc.), Underwriting Agreement (Apogee Therapeutics, Inc.)
Emerging Growth Company Status. From the time of the initial confidential submission of the Registration Statement to the Commission (or, if earlier, the first date on which the Company engaged in any Section 5(d) Written Communication or any Section 5(d) Oral Communication) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).
Appears in 116 contracts
Samples: Underwriting Agreement (Perceptive Capital Solutions Corp), Underwriting Agreement (Perceptive Capital Solutions Corp), Underwriting Agreement (Oaktree Acquisition Corp. III Life Sciences)
Emerging Growth Company Status. From Since the time of the initial confidential submission filing of the Registration Statement to with the Commission (or, if earlier, the first date on which the Company engaged in any Section 5(d) Written Communication or any Section 5(d) Oral Communication) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).
Appears in 8 contracts
Samples: Underwriting Agreement (Medpace Holdings, Inc.), Underwriting Agreement (Medpace Holdings, Inc.), Underwriting Agreement (Medpace Holdings, Inc.)
Emerging Growth Company Status. From the time of initial confidential submission of the Registration Statement to the Commission (or, if earlier, the first date on which the Company engaged in any Section 5(d) Written Communication or any Section 5(d) Oral Communication) Communication through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).
Appears in 6 contracts
Samples: Underwriting Agreement (Eiger BioPharmaceuticals, Inc.), Underwriting Agreement (Milestone Pharmaceuticals Inc.), Underwriting Agreement (Eiger BioPharmaceuticals, Inc.)
Emerging Growth Company Status. From the time of initial confidential submission filing of the Registration Statement to the Commission (or, if earlier, the first date on which the Company engaged in any Section 5(d) Written Communication or any Section 5(d) Oral Communication) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).
Appears in 6 contracts
Samples: Underwriting Agreement (Ardelyx, Inc.), Underwriting Agreement (Spring Bank Pharmaceuticals, Inc.), Underwriting Agreement (Ardelyx, Inc.)
Emerging Growth Company Status. From the time of initial confidential submission of the Registration Statement registration statement relating to the Company’s initial public offering to the Commission (or, if earlier, the first date on which the Company engaged in any Section 5(d) Written Communication or any Section 5(d) Oral Communication) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).
Appears in 6 contracts
Samples: Underwriting Agreement (Tourmaline Bio, Inc.), Underwriting Agreement (Alx Oncology Holdings Inc), Underwriting Agreement (Arcellx, Inc.)
Emerging Growth Company Status. From the time of initial confidential submission filing of the Registration Statement to with the Commission (or, if earlier, the first date on which the Company engaged in any Section 5(d) Written Communication or any Section 5(d) Oral Communication) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).
Appears in 5 contracts
Samples: Underwriting Agreement (NewAmsterdam Pharma Co N.V.), Underwriting Agreement (BELLUS Health Inc.), Underwriting Agreement (Absolute Software Corp)
Emerging Growth Company Status. From the time of initial confidential submission of the Registration Statement to the Commission (orIf applicable, if earlier, from the first date on which the Company engaged in any Section 5(d) Written Communication or any Section 5(d) Oral Communication) Communication through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).
Appears in 4 contracts
Samples: Sales Agreement (Osmotica Pharmaceuticals PLC), Underwriting Agreement (Osmotica Pharmaceuticals PLC), Underwriting Agreement (Osmotica Pharmaceuticals PLC)
Emerging Growth Company Status. From the time of initial confidential submission filing of the Registration Statement to the Commission (or, if earlier, the first date on which the Company engaged in any a Section 5(d) Written Communication or any Section 5(d) Oral Communicationwas made) through the date hereof, the Company Partnership has been and is an “emerging growth company,” as defined in Section 2(a2(a)(19) of the Securities Act (an “Emerging Growth Company”).
Appears in 4 contracts
Samples: Underwriting Agreement (Hess Midstream Partners LP), Underwriting Agreement (Hess Midstream Partners LP), Underwriting Agreement (Hess Midstream Partners LP)
Emerging Growth Company Status. From the time of initial confidential submission of the Registration Statement registration statement to the Commission in connection with the Company’s initial public offering (or, if earlier, the first date on which the Company engaged in any Section 5(d) Written Communication or any Section 5(d) Oral Communication) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).
Appears in 4 contracts
Samples: Open Market Sale Agreement (Sierra Oncology, Inc.), Underwriting Agreement (Sierra Oncology, Inc.), Underwriting Agreement (Sierra Oncology, Inc.)
Emerging Growth Company Status. From the time of initial confidential submission filing of the Registration Statement to with the Commission (or, if earlier, the first date on which the Company engaged directly or through any Person authorized to act on its behalf in any Section 5(d) Written Communication Communications or any Section 5(d) Oral CommunicationCommunications) through the date hereofApplicable Time, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).
Appears in 4 contracts
Samples: Underwriting Agreement (Cidara Therapeutics, Inc.), Underwriting Agreement (Cidara Therapeutics, Inc.), Underwriting Agreement (Cidara Therapeutics, Inc.)
Emerging Growth Company Status. From the time of initial confidential submission of the Registration Statement to the Commission (or, if earlier, the first date on which the Company engaged in any Section 5(d) Written Communication or any Section 5(d) Oral Communication) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).
Appears in 3 contracts
Samples: Open Market Sale Agreement (Sesen Bio, Inc.), Underwriting Agreement (Sesen Bio, Inc.), Underwriting Agreement (Sesen Bio, Inc.)
Emerging Growth Company Status. From the time of initial confidential submission of the Registration Statement registration statement relating to the Company’s initial public offering to the Commission (or, if earlier, the first date on which the Company engaged in any Section 5(d) Written Communication or any Section 5(d) Oral Communication) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities 1933 Act (an “Emerging Growth Company”).
Appears in 2 contracts
Samples: At the Market Equity Offering Sales Agreement (Xenon Pharmaceuticals Inc.), At the Market Equity Offering Sales Agreement (Xenon Pharmaceuticals Inc.)
Emerging Growth Company Status. From the time of initial confidential submission filing of the Registration Statement to with the Commission (or, if earlier, the first date on which the Company engaged in any Section 5(d) Written Communication or any Section 5(d) Oral Communication) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a2(a)(19) of the Securities Act (an “Emerging Growth Company”).
Appears in 2 contracts
Samples: Underwriting Agreement (Auris Medical Holding AG), Underwriting Agreement (Affimed N.V.)
Emerging Growth Company Status. From the time of initial confidential submission filing of the Registration Statement to with the Commission (or, if earlier, the first date on which the Company engaged in any Section 5(d) Written Communication or any Section 5(d) Oral Communication) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).
Appears in 2 contracts
Samples: Underwriting Agreement (Zynerba Pharmaceuticals, Inc.), Underwriting Agreement (Zynerba Pharmaceuticals, Inc.)
Emerging Growth Company Status. From the time of initial confidential submission of the Registration Statement to the Commission (or, if earlier, the first date on which the Company engaged in any Section 5(d) Written Communication or any Section 5(d) Oral Communication) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a2(a)(19) of the Securities Act (an “Emerging Growth Company”).
Appears in 2 contracts
Samples: Underwriting Agreement (Auris Medical Holding AG), Underwriting Agreement (Affimed Therapeutics B.V.)
Emerging Growth Company Status. From the time of the initial confidential submission of the Registration Statement to the Commission (or, if earlier, the first date on which the Company engaged directly or through any Person authorized to act on its behalf in any oral or written communication with potential investors undertaken in reliance on Section 5(d) Written Communication or any Section 5(d) Oral Communicationof the Securities Act) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).
Appears in 2 contracts
Samples: Sales Agreement (Spero Therapeutics, Inc.), Sales Agreement (Spero Therapeutics, Inc.)
Emerging Growth Company Status. From the time of initial confidential submission of the Registration Statement to the Commission of the Company’s Registration Statement on Form S-1 (File No. 333-193150) (or, if earlier, the first date on which the Company engaged in any Section 5(d) Written Communication or any Section 5(d) Oral Communication) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”)Act.
Appears in 2 contracts
Samples: Sales Agreement (Dicerna Pharmaceuticals Inc), Sales Agreement (Dicerna Pharmaceuticals Inc)
Emerging Growth Company Status. From the time of initial confidential submission of the Registration Statement to the Commission (or, if earlier, the first date on which the Company engaged in any Section 5(d) Written Communication or any Section 5(d) Oral Communication) Communication through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).
Appears in 2 contracts
Samples: Underwriting Agreement (Kezar Life Sciences, Inc.), Underwriting Agreement (Kezar Life Sciences, Inc.)
Emerging Growth Company Status. From the time of the initial confidential submission filing of the Registration Statement to with the Commission (or, if earlier, the first date on which the Company engaged in any Section 5(d) Written Communication or any Section 5(d) Oral Communication) through the date hereofDecember 31, 2023, the Company has been and is was an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).
Appears in 1 contract
Emerging Growth Company Status. From the time of the initial confidential submission filing of the Registration Statement to the Commission (or, if earlier, the first date on which the Company engaged in any Section 5(d) Written Communication or any Section 5(d) Oral Communication) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).
Appears in 1 contract
Samples: Underwriting Agreement (Supernus Pharmaceuticals Inc)
Emerging Growth Company Status. From the time of the initial confidential submission filing of the Registration Statement to with the Commission (or, if earlier, the first date on which the Company engaged in any Section 5(d) Written Communication or any Section 5(d) Oral Communication) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).
Appears in 1 contract
Samples: Underwriting Agreement (Live Oak Crestview Climate Acquisition Corp.)
Emerging Growth Company Status. From the time of initial confidential submission of the Registration Statement registration statement to the Commission relating to the Company’s initial public offering (or, if earlier, the first date on which the Company engaged in any Section 5(d) Written Communication or any Section 5(d) Oral Communication) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).
Appears in 1 contract
Samples: Underwriting Agreement (Pieris Pharmaceuticals, Inc.)
Emerging Growth Company Status. From the time of initial confidential submission of the Registration Statement to the Commission (or, if earlier, the first date on which the Company engaged in any Section 5(d) Written Communication or any Section 5(d) Oral Communication) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”). .
Appears in 1 contract
Emerging Growth Company Status. From the time of initial confidential submission of the Registration Statement to the Commission (or, if earlier, the first date on which the Company engaged directly or through any Person authorized to act on its behalf in any communication in reliance on Section 5(d) Written Communication or any Section 5(d) Oral Communicationof the 0000 Xxx) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities 1933 Act (an “Emerging Growth Company”).
Appears in 1 contract
Emerging Growth Company Status. From the time of initial confidential submission of the Registration Statement to the Commission (or, if earlier, the first date on which the Company engaged in any written or oral communications in reliance on Section 5(d) Written Communication or any Section 5(d) Oral Communicationof the 0000 Xxx) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities 1933 Act (an “Emerging Growth Company”).
Appears in 1 contract
Samples: Underwriting Agreement (Tracon Pharmaceuticals, Inc.)
Emerging Growth Company Status. From the time of the initial confidential submission of the Registration Statement registration statement to the Commission (or, if earlier, the first date on which the Company engaged in any Section 5(d) Written Communication or any Section 5(d) Oral Communication) in connection with the Company’s initial public offering through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).
Appears in 1 contract
Samples: Underwriting Agreement (Five Prime Therapeutics Inc)
Emerging Growth Company Status. From the time of initial confidential submission of the Registration Statement to the Commission (or, if earlier, the first date on which the Company engaged directly or through any Person authorized to act on its behalf in any communication in reliance on Section 5(d) Written Communication or any Section 5(d) Oral Communicationof the Securities Act) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).
Appears in 1 contract
Emerging Growth Company Status. From the time of initial confidential submission the filing of the Initial Registration Statement to the Commission (or, if earlier, the first date on which the Company engaged in any written or oral communications in reliance on Section 5(d) Written Communication or any Section 5(d) Oral Communicationof the 0000 Xxx) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities 1933 Act (an “Emerging Growth Company”).
Appears in 1 contract
Samples: Underwriting Agreement (Tracon Pharmaceuticals, Inc.)
Emerging Growth Company Status. From the time of initial confidential submission of the Registration Statement to the Commission (or, if earlier, the first date on which the Company engaged in any Section 5(d) Written Communication or any Section 5(d) Oral Communication) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”). The Company will no longer be an Emerging Growth Company beginning on December 31, 2017.
Appears in 1 contract
Samples: Underwriting Agreement (National Storage Affiliates Trust)
Emerging Growth Company Status. From the time of initial confidential submission of amendment no. 5 to the Registration Statement to filed with the Commission on May 16, 2012 (or, if earlier, the first date on which the Company engaged in any Section 5(d) Written Communication or any Section 5(d) Oral Communication) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).
Appears in 1 contract
Emerging Growth Company Status. From the time of initial confidential submission of the Registration Statement registration statement to the Commission (or, if earlier, the first date on which the Company engaged in any Section 5(d) Written Communication or any Section 5(d) Oral Communication) in connection with the Company’s initial public offering through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).
Appears in 1 contract
Samples: Underwriting Agreement (Five Prime Therapeutics Inc)
Emerging Growth Company Status. From the time of initial confidential submission of the Registration Statement registration statement relating to the Company’s initial public offering to the Commission (or, if earlier, the first date on which the Company engaged in any Section 5(d) Written Communication or any Section 5(d) Oral Communication) through the date hereofof this Agreement, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities 1933 Act (an “Emerging Growth Company”).
Appears in 1 contract
Samples: At the Market Equity Offering Sales Agreement (Xenon Pharmaceuticals Inc.)
Emerging Growth Company Status. From the time of initial confidential submission the filing of the Registration Statement to with the Commission (or, if earlier, the first date on which the Company engaged in any Section 5(d) Written Communication or any Section 5(d) Oral Communication) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).
Appears in 1 contract
Emerging Growth Company Status. From the time of initial confidential submission of the Registration Statement a registration statement to the Commission (or, if earlier, the first date on which the Company engaged in any Section 5(d) Written Communication or any Section 5(d) Oral Communication) in connection with the Company’s initial public offering through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).
Appears in 1 contract
Samples: Open Market Sale Agreement (Ventyx Biosciences, Inc.)
Emerging Growth Company Status. From the time of initial confidential submission of the Registration Statement registration statement relating to the Company’s initial public offering to the Commission (or, if earlier, the first date on which the Company engaged in any Section 5(d) Written Communication or any Section 5(d) Oral Communication) through the effective date hereofof the Registration Statement, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities 1933 Act (an “Emerging Growth Company”).
Appears in 1 contract
Samples: At the Market Equity Offering Sales Agreement (Arcellx, Inc.)
Emerging Growth Company Status. From the time of initial confidential submission first filing of the Registration Statement to with the Commission (or, if earlier, the first date on which the Company engaged directly or through any Person authorized to act on its behalf in any communication in reliance on Section 5(d) Written Communication or any Section 5(d) Oral Communicationof the Act) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).
Appears in 1 contract
Samples: Underwriting Agreement (Community Choice Financial Inc.)
Emerging Growth Company Status. From the time of the initial confidential submission of the Registration Statement initial registration statement to the Commission during the Company’s initial public offering (or, if earlier, the first date on which the Company engaged directly or through any person authorized to act on its behalf in any Permitted Section 5(d) Written Communication or any Section 5(d) Oral CommunicationCommunications) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).
Appears in 1 contract
Emerging Growth Company Status. From the time of initial confidential submission first filing of the Registration Statement to with the Commission (or, if earlier, the first date on which the Company engaged directly or through any person authorized to act on its behalf in any communication in reliance on Section 5(d) Written Communication or any Section 5(d) Oral Communicationof the Act) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).
Appears in 1 contract
Emerging Growth Company Status. From the time of the initial confidential submission of the Registration Statement to the Commission (or, if earlier, the first date on which the Company engaged directly or through any person authorized to act on its behalf in any oral or written communication in reliance on Section 5(d) Written Communication or any Section 5(d) Oral Communicationof the 0000 Xxx) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities 1933 Act (an “Emerging Growth Company”).
Appears in 1 contract
Samples: Underwriting Agreement (Tabula Rasa HealthCare, Inc.)
Emerging Growth Company Status. From the time of initial confidential submission of the Registration Statement registration statement relating to the Company’s initial public offering with the Commission (or, if earlier, the first date on which the Company engaged in any Section 5(d) Written Communication or any Section 5(d) Oral Communication) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a2(a)(19) of the Securities Act (an “Emerging Growth Company”).
Appears in 1 contract
Emerging Growth Company Status. From Since the time of initial confidential submission filing of the Registration Statement to with the Commission (or, if earlier, the first date on which the Company engaged in any Section 5(d) Written Communication or any Section 5(d) Oral Communication) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).
Appears in 1 contract
Samples: Underwriting Agreement (Marrone Bio Innovations Inc)
